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The in vitro cytotoxicity and in vivo efficacy of 1-(2-
chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) can
be markedly enhanced in combination with certain
radiation sensitizing compounds (reviewed by
Siemann, 1982), most notably Misonidazole
(MISO). CCNU, like other nitrosoureas, undergoes
a spontaneous chemical decomposition to yield two
active species, an alkylating chloroethyl carbonium
ion as well as a carbamoylating isocyanate
(Montgomery et al., 1967). Alkylation is considered
to be responsible for cytotoxicity (Wheeler et al.,
1974), while carbamoylation can account for the
inhibition of protein-mediated processes such as the
repair of DNA damage (Kann et al., 1980) and the
regeneration of intracellular glutatione (Babson &
Reed, 1978). When administered in vivo certain
nitrosoureas, including CCNU, are modified by
hepatic mixed-function oxidases prior to their
decomposition to therapeutically active species. In
the case of CCNU, the cyclohexyl ring of the
parent drug is rapidly hydroxylated at multiple sites
to yield a mixture of cis- and trans- hydroxylated
analogs, some of which have properties significantly
different from those of the parent compound (May
et al., 1974; Hilton & Walter, 1975; Wheeler et al.,
1977). As these analogs are believed to be the
immediate precursors of active moieties, it is likely
that the chemopotentiation observed when MISO is
combined with CCNU in vivo represents a
composite of the interactions of MISO with the
individual hydroxylated CCNUs or the damage
induced by these agents. In order to determine
whether MISO can potentiate the cytotoxicity of
individual CCNU metabolites EMT-6/Ro tumour
cells were treated in vitro with MISO combined
with four hydroxylated metabolites of CCNU: cis:
and trans-2-OH CCNU and cis- and trans-4-OH
CCNU. The latter represent the major metabolites
recovered from the plasma of humans and rodents
treated with CCNU.
Although chemopotentiation can be induced in
EMT-6/Ro cell cultures treated at oxygen tensions
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between fully aerobic and radiobiologically hypoxic,
the magnitude of enhancement is greatest under
hypoxic conditions (Mulcahy, 1984). Therefore, for
these experiments EMT-6/Ro cells were treated
with each of the nitrosoureas alone or in
combination with 1.0mM MISO under hypoxic
conditions (< 10ppm 02). Details of the
experimental methodology are described in detail
elsewhere (Mulcahy et al., 1984). Briefly, for each
treatment group 10.0ml of complete BME medium
was gassed for 3 h with a 97% N2/3% CO2 gas
mixture while being stirred. At the conclusion of
the gassing phase cells were injected onto each of
the treatment vials. Prior to injection the cells were
incubated for 10min at a concentration of
-2x 107ml-1 in a Hamilton air-tight syringe at
37°C to reduce oxygen by consumption. In separate
experiments it was determined that this treatment
did not influence the response of EMT-6/Ro cells
to subsequent nitrosourea treatment.
To initiate exposure, various concentrations of
the nitrosoureas were injected into each of the
treatment vials, without interrupting gassing. The
nitrosoureas were initially dissolved in absolute
ethanol and were diluted 1:100 upon addition to
the treatment vials. The final concentration of
alcohol (1%) did not significantly influence the
plating efficiency relative to controls. For those
experiments in which cells were exposed to MISO
and the nitrosoureas simultaneously, MISO was
dissolved in complete BME at a concentration of
1.0mM prior to the initiation of the gassing
sequence. During the entire exposure period the
vials were continuously purged with the gas
mixture. Four hours after injection of the drugs the
medium containing drugs and cells was removed
from each vial. The cells were centrifuged, washed
and resuspended in fresh BME. Survival was
determined using a standard plating efficiency
assay. Survival curves were generated by fitting the
data to a linear quadratic model by least squares
analysis. Dose Enhancement Factors (DEF; defined
as the ratio of nitrosourea doses required to reduce
cell survival to 0.001 alone or in combination with
MISO) were determined from the resultant dose
response curves according to the following
equation:
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Figure 1 Dose response curves for each of the monohydroxylated-CCNU metabolites (X) and CCNU (0)
(a) cis-4-OH CCNU; (b) cis-2-OH CCNU; (c) trans-4-OH CCNU; (d) trans-2-OH CCNU. The dotted line in
the last 3 panels represents the dose response curve for CCNU redrawn from the data graphed in the first
panel (0). (+) Are survival data for EMT-6/Ro cells treated with monohydroxylated-CCNU metabolites and
1.0mM MISO under hypoxic conditions. The data represent the pooled results of from 2-4 separate
experiments for each compound.
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DEF= -c +(a2+4fl D(am +pmD))1/2#f D, where
c, f3c are the a, f parameters for cells treated with
nitrosourea alone and am, Pm are the parameters for
cells treated with nitrosourea and 1.0mM MISO;
D=dose.
The cytotoxicity of the trans-2-OH or trans-4-OH
analogue was not significantly different from that
for CCNU (analysis of covaraince; P>0.1).
However, cis-4-OH CCNU was significantly more
toxic than CCNU, while the cis-2-OH isomer was
significantly less effective (analysis of covariance;
P<0.05). Cytotoxicity of all four isomers was
significantly (P<0.01) enhanced in combination
with 1.0mM MISO (Figure 1). DEFs (95% conf.
int.) of 1.3 (1.2-1.4), 2.0 (1.8-2.2), 1.8 (1.7-1.9) and
1.7 (1.6-1.9) were produced when MISO was
combined with cis-4-OH, trans-2-OH, cis-2-OH and
trans-4-OH CCNU, respectively. The enhancements
for the latter three drugs are comparable to those
observed when MISO is combined with the parent
CCNU in vitro (DEF= 1.6-1.8; Mulcahy et al.,
1984).
These studies indicate that MISO is capable of
enhancing the cytotoxicity of monohydroxy-CCNU
metabolites, as well as CCNU in vitro. Since in
previous studies compounds enhanced by MISO in
vitro have been similarly enhanced in vivo
(Mulcahy, 1982; Mulcahy et al., 1984), it seems
likely that the effectiveness of the monohydroxy-
lated analogues of CCNU, the major metabolites
and immediate precursors of alkylating and
carbamoylating moieties, will be potentiated in
combination with MISO in vivo. This may be
important in relation to the observations by Lee &
Workman (1983) that the concentrations of the
major CCNU metabolites are elevated following
administration of large single doses of MISO. They
maintain that the pharmacokinetic alterations
observed subsequent to MISO administration are a
major factor in the chemopotentiation of CCNU.
While the increase in the concentration of these
cytotoxic moieties undoubtedly contributes to the
enhancement of CCNU cytotoxicity by large doses
of MISO in vivo, our investigations suggest that
MISO is capable of interacting with the major
metabolites of CCNU in a non-pharmacokinetic
fashion to enhance their cytotoxicity. We contend
that this interaction may actually predominate
when lower doses of MISO are employed. Since the
enhancements produced when MISO is combined
with hydroxylated metabolites of CCNU are, in
general, comparable to those observed for CCNU
itself, MISO-induced alterations in the rate of
CCNU conversion or in the distribution of major
monohydroxylated products are unlikely to
adversely effect the enhancement of toxicity in vivo.
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